The European Lung Foundation (ELF)Founded by ERS in 2000, ELF brings together patients and the public with respiratory professionals to positively influence lung health.Visit the ELF site
ERS Lung Science ConferenceJoin us for this year’s virtual event (11–12 March). The theme is ‘Repair and regeneration in chronic lung disease and lung cancer’.Find out more/register
Sleep and Breathing 2021Taking place in April, this is the largest pan-European meeting of its kind and offers an integrated approach to the investigation and treatment of sleep disorders.Find out more/register
e-GLILDnet – A European Granulomatous-Lymphocytic Interstitial Lung Disease Network
CRC Chairs : Prof. John Hurst (University College of London, London, UK) Prof. Klaus Warnatz (University of Freiburg, Freiburg, Germany)
/* Main content & Sidebar */ ?>
About eGLILDnet
The e-GLILDnet (European Granulomatous-Lymphocytic Interstitial Lung Disease Network) Clinical Research Collaboration was launched by the European Respiratory Society (ERS) in 2019, in association with the European Society for Immunodeficiencies (ESID), European Lung Foundation (ELF) and the International Patient Organisation for Primary Immunodeficiencies (IPOPI). It is a collaboration of clinicians and scientists from across Europe dedicated to improving the lives of those living with Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD), a lung complication seen in people affected by primary immunodeficiency, particularly common variable immunodeficiency disorders (CVID). GLILD is the lung component of a systemic autoimmune/auto-inflammatory component of CVID that can result in reduced survival, is resistant to antibody replacement, and for which there is very little evidence based-therapy. Therapeutic potential is increasing rapidly with the identification of specific mechanisms underlying GLILD. Only by adopting a multi-professional Europe-wide approach in GLILD can we deliver practice-changing research and improve the lives of people living with this condition.
Specific aims
To bring together clinicians, researchers and patient representatives, from across Europe, to prioritise research questions in GLILD using Delphi methodology. The Delphi will be published.
To develop a research protocol to address our top research priority.
To establish a panel of experts across respiratory medicine, immunology, pathology and radiology to act as a virtual multi-disciplinary team (vMDT) in which new and treatment-resistant GLILD cases from across Europe can be discussed, with advice provided on diagnosis and management. This is modelled on the well-established and successful local respiratory-immunology multi-disciplinary teams (MDT) in London, and the clinical CCI conference in Freiburg. Participating sites would be encouraged to biobank samples for future collaborative analyses.
To define the content of, and secure approvals to establish a European database for GLILD. Thus, over time, in addition to improving patient care, MDT cases will be entered into a database to provide a prospective research registry and outcome resource, which can be linked back to radiology, pathology, treatment and – where stored – analysis of biological samples such as blood and broncho-alveolar lavage.
To support and encourage early-career researchers in the field of respiratory-immunology through involvement in network activities.
Stakeholders
The e-GLILDnet Steering Committee is composed of the two CRC chairs, multi-professional clinicians and researchers, two early-career researchers (one ERS, one ESID) and patient representatives. It currently includes pulmonologists, immunologists, radiologists and pathologists from eight European countries and is actively making links with other centres across Europe.
The Stakeholder Board comprises a partnership between the different stakeholders e.g Steering Committee, national centres leads, funding partners, scientific experts, and patient advisory groups.
These two groups will combine their expertise in e-GLILDnet to act as the go-to resource of clinical experience in GLILD for patients and clinicians, and as a network to conduct clinical trials and basic research in GLILD.
Contact
If you are interested in more information about e-GLILDnet or would like to join the registry, please contact scientific@ersnet.org.
Follow the progress of e-GLILDnet on Twitter: @glildnet
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.